FNCH
Price:
$11.95
Market Cap:
$19.19M
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis ...[Read more]
Industry
Biotechnology
IPO Date
2021-03-19
Stock Exchange
NASDAQ
Ticker
FNCH
According to Finch Therapeutics Group, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 32.14M. This represents a change of 161.73% compared to the average of 12.28M of the last 4 quarters.
The mean historical Enterprise Value of Finch Therapeutics Group, Inc. over the last ten years is 484.51M. The current 32.14M Enterprise Value has changed 563.41% with respect to the historical average. Over the past ten years (40 quarters), FNCH's Enterprise Value was at its highest in in the June 2021 quarter at 498.50M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.
Average
484.51M
Median
346.23M
Minimum
4.19M
Maximum
1.13B
Discovering the peaks and valleys of Finch Therapeutics Group, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 157.44%
Maximum Annual Enterprise Value = 1.13B
Minimum Annual Increase = -98.79%
Minimum Annual Enterprise Value = 4.19M
Year | Enterprise Value | Change |
---|---|---|
2023 | 10.79M | 157.44% |
2022 | 4.19M | -98.79% |
2021 | 346.23M | -62.82% |
2020 | 931.22M | -17.60% |
The current Enterprise Value of Finch Therapeutics Group, Inc. (FNCH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
120.41M
5-year avg
484.51M
10-year avg
484.51M
Finch Therapeutics Group, Inc.’s Enterprise Value is greater than Werewolf Therapeutics, Inc. (139.97K), less than Edgewise Therapeutics, Inc. (3.19B), less than Decibel Therapeutics, Inc. (96.42M), less than Celcuity Inc. (634.84M), less than C4 Therapeutics, Inc. (462.75M), less than Ikena Oncology, Inc. (47.83M), less than Design Therapeutics, Inc. (258.23M), greater than Xilio Therapeutics, Inc. (-2975414.00), less than Eliem Therapeutics, Inc. (119.64M), less than Monte Rosa Therapeutics, Inc. (478.04M), less than Stoke Therapeutics, Inc. (501.96M), greater than Virax Biolabs Group Limited (5.49M), greater than Blue Water Vaccines, Inc. (8.67M), greater than Revelation Biosciences, Inc. (-8886223.00), greater than Hillstream BioPharma, Inc. (1.48M), greater than Kiora Pharmaceuticals, Inc. (4.42M), less than Nutriband Inc. (57.98M), greater than Quoin Pharmaceuticals, Ltd. (3.24M), greater than Longeveron Inc. (20.39M), greater than RenovoRx, Inc. (13.20M),
Company | Enterprise Value | Market cap |
---|---|---|
139.97K | $98.77M | |
3.19B | $3.23B | |
96.42M | $123.37M | |
634.84M | $568.78M | |
462.75M | $455.30M | |
47.83M | $83.00M | |
258.23M | $301.22M | |
-2975414.00 | $63.29M | |
119.64M | $342.68M | |
478.04M | $542.54M | |
501.96M | $689.69M | |
5.49M | $8.86M | |
8.67M | $3.41M | |
-8886223.00 | $3.19M | |
1.48M | $4.17M | |
4.42M | $10.92M | |
57.98M | $64.53M | |
3.24M | $2.86M | |
20.39M | $31.02M | |
13.20M | $24.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Finch Therapeutics Group, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Finch Therapeutics Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Finch Therapeutics Group, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Finch Therapeutics Group, Inc. (FNCH)?
What is the 3-year average Enterprise Value for Finch Therapeutics Group, Inc. (FNCH)?
What is the 5-year average Enterprise Value for Finch Therapeutics Group, Inc. (FNCH)?
How does the current Enterprise Value for Finch Therapeutics Group, Inc. (FNCH) compare to its historical average?